

## **Sequist, Lecia**

### **Institution/Organization**

Massachusetts General Hospital

### **Primary Specialty**

Medical Oncology

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

#### **Disclosures**

AstraZeneca: Consulting

AstraZeneca: Clinical trial funding; Up to 2021

Genentech: Data Safety Monitoring Committee; Up to 2021

Massachusetts General Hospital: Primary site of Employment

American Lung Association: Educational lecture; 2020

American Society of Clinical Oncology: Educational lecture; 2019

BioAscend: Educational lecture; 2020

Clinical Care Options: Educational lecture; 2021

Creative Educational Concepts: Lecture and course director Personal; Up to 2021

Dana Farber Cancer Institute: Lecture; 2019

E-vate LTD: Consulting; 2020

Flagship Labs 67, Inc: consulting; 2020

Harvard University: Educational lecture; 2019

Inception Digital: Educational lecture; 2019

Intellisphere, LLC: Educational lecture; 2019

Janssen: Educational lecture; 2020

National Cancer Institute: Steering Committee; Up to 2021

LUNGeivity: Scientific Advisory Board; Up to 2021

MJH Healthcare Holdings, LLC: Educational Lecture; Up to 2021

Nexus Global Group Science, LLC: Consulting; 2019

Ohio State University: Educational Lecture; 2021

Peer View, LLC: Educational Lecture; 2021

PlatformQ Health, Inc: Consulting; 2019

Prime Oncology: Educational lecture; 2019

PSL Group Americas: Educational Lecture; 2019

Research To Practice: Educational Lecture; Up to 2021

Touch Medical Media: Educational Lecture; 2021

Triptych Health Partners: Educational Lecture; 2021

UpToDate: Writing; Up to 2021

WebMD: Educational lectures and course director; up to 2021

Novartis: Clinical Trial

Delfi: Clinical Trial

**COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agreed

**Standards of Conduct Agreement**

Agreed

**IASLC's Tax-Exempt Status**

Agreed

**COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

I serve as the PI for the following clinical trials at my institution (2019-2021):

1. A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with EGFRm, Metastatic NSCLC who have Progressed Extracranially following First-Line Osimertinib Therapy (COMPEL), funded by AstraZeneca
2. A Multi-center, AZD9291 Expanded Access Program for the Treatment of Patients with Advanced/Metastatic EGFR T790M Mutation-Positive Non-small Cell Lung Cancer (NSCLC) Who Have Received Prior EGFR TKI Therapy, funded by AstraZeneca
3. A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a standard of care epidermal growth factor receptor Tyrosine Kinase Inhibitor as First-Line treatment in patients with epidermal growth factor receptor mutation positive, locally advanced or metastatic non-small cell lung cancer, funded by AstraZeneca
4. A Multi-arm, Phase Ib, Open-Label, Multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9291 in combination with ascending doses of novel therapeutics in patients with EGFRm+ advanced NSCLC who has progressed following therapy with an EGFR TKI (TATTON), funded by AstraZeneca
5. A Phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer, funded by Novartis

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

1. LUNGeivity, Scientific Advisory Board
2. American Lung Association, Massachusetts Leadership Board, Scientific and Medical Editorial Review Panel, and Chair of the local Lung Force Expo meeting
3. Member, Board of Directors, Upstage Lung Cancer Foundation
4. Oregon Health Sciences University Cancer Early Detection and Advanced Research Center, External Advisory Committee
5. Leader, Cancer Risk, Prevention, and Early Detection Program, Dana-Farber Harvard Cancer Center
6. The Fleischner Study, Member-Elect

7. NCI Thoracic Malignancy Steering Committee, member
8. American Society of Clinical Oncology: Thoracic Cancer Guideline Advisory Group, Cancer Prevention Committee, and Virtual Mentorship Program
9. The Oncology Journal: Lung cancer section editor
10. Eastern Cooperative Oncology Group: lung cancer core committee
11. American Association for Cancer Research: Lung Cancer Research Grants Scientific Review Committee, Chair, Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research Selection Committee
12. European Society of Medical Oncology, Contributor, EGFR mutation positive lung cancer consensus guidelines and member, Scientific Committee
13. American Cancer Society, PI for a grant which gives out institutional research grants
14. Zhu Family Center for Global Cancer Prevention, Harvard T.H. Chan School of Public Health, member

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

Yes, they are all disclosed above

**Are you conducting clinical trials with any oncology equipment companies?**

Yes

**Please disclose the names of any oncology equipment companies for which you are conducting any clinical trials.**

Will be opening a clinical trial soon with a blood test made by Delfi Diagnostics